Over the last decade, the availability of non-vitamin K antago- nist oral anticoagulants (NOACs) has significantly changed the daily clinical practice in managing thromboembolic risk in patients with atrial fibrillation (AF).1 Guidelines for AF man- agement have established that NOACs are the preferred treat- ment for the majority of AF patients;2 however, recent data from ‘real-life’ registries clearly show that a significant pro- portion of patients are still treated with vitamin K antago- nists.3–8 Nevertheless, the role of NOACs still seems to be debated in some specific circumstances, such as their role in the peri-operative management of patients with AF, in relation to interruption or continuation of anticoagulation.
Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation : To Stop, Bridge or Continue? / M. Proietti, D.A. Lane. - In: THROMBOSIS AND HAEMOSTASIS. - ISSN 0340-6245. - 118:7(2018 Jul), pp. 1123-1126.
|Titolo:||Use of NOACs in the Peri-Operative Management of Patients with Atrial Fibrillation : To Stop, Bridge or Continue?|
PROIETTI, MARCO (Primo) (Corresponding)
|Settore Scientifico Disciplinare:||Settore MED/11 - Malattie dell'Apparato Cardiovascolare|
|Data di pubblicazione:||lug-2018|
|Digital Object Identifier (DOI):||http://dx.doi.org/10.1055/s-0038-1661370|
|Appare nelle tipologie:||01 - Articolo su periodico|